Lindgreen Raymond

PURPOSE To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. METHODS A total of 100 ovarian cancer patients treated in our hospital from January 2015 to December 2018 were enrolled and divided into experimental group (n=50) and control group…[Read more]

However, there were no statistically significant differences (p > 0.05) for metallic ions concentrations between Group A and Group B. CONCLUSIONS Based on our results, there are no differences in titanium or other metals concentrations in saliva of patients with healthy or diseased implants.Commercially and traditionally managed bees were compared…[Read more]

Factors associated with elevated ESCC risk in this analysis included advanced age, being male and smoking. We further identified that the XRCC1 399 Gln/Gln genotype was associated with a significant reduction in ESCC risk prior to propensity matching (odds ratio=0.48; 95% CI 0.23-1.00; P less then 0.05), although this did not remain true following…[Read more]